INTRODUCTION
Acute kidney injury (AKI) is a formidable complication of cardiac surgery. Depending on how it is defined and its severity, the incidence of cardiac surgery-associated AKI (CSA-AKI) varies widely, from 7 to 40% in large patient cohorts undergoing a variety of procedures [1] [2] [3] [4] . The incidence of CSA-AKI increases to as high as 50% in groups of patients with known risk factors [5 & ,6 ]. As implied above, the wide range of incidence of CSA-AKI depends on its definition. The severity of CSA-AKI ranges from asymptomatic increases in biochemical markers of renal injury that are of little clinical consequence, to the requirement for renal replacement therapy (RRT) that has a dramatic impact on ICU and hospital length of stay (LOS), as well as operative mortality [7] [8] [9] . At its most severe extreme, new onset CSA-AKI increases the odds of operative mortality three to eight-fold [10, 11] .
The association between CSA-AKI and poor outcome has been appreciated for many years. Considerable progress has been made in more accurate definition of the syndrome and greater understanding of its pathophysiology, and yet the early detection, prevention, and management CSA-AKI remains a substantial challenge. The assumption remains prevalent that a decrease in the incidence in CSA-AKI will decrease perioperative morbidity and mortality, and that the development of CSA-AKI is modifiable [12] . However, the pathogenesis of perioperative CSA-AKI may be more closely related to the stage of preoperative chronic kidney disease (CKD) and the severity of perioperative cardiac dysfunction, and may explain the lack of success of so many specific 'renal' interventions.
In this review, the focus is on studies published within the last 18 months (January 2013 to August 2014) that provide an update on CSA-AKI. For an It is very unlikely that a single etiologic factor will cause perioperative AKI. Almost inevitably, CSA-AKI is the consequence of multiple, interactive pathways. Patients may be more susceptible to CSA-AKI by virtue of their sex, age, pre-existing cardiac dysfunction, pre-existing CKD, previous cardiac surgery, or comorbidity such as chronic obstructive pulmonary disease or diabetes mellitus [14] . Perioperative administration of nephrotoxic agents, such as radiocontrast dyes, angiotensinconverting enzyme inhibitors, loop diuretics, or aminoglycoside antibiotics, can enhance the likelihood of CSA-AKI [14] . These agents seldom act in isolation; it is a truism that the risk of nephrotoxicity is exponentially related to the number of nephrotoxic insults, which includes a milieu of intravascular hypovolemia or hemodynamic instability. Perhaps the greatest influence on renal outcome is the complexity and emergent nature of the cardiac surgical procedure, resulting in the so-called cardiorenal syndrome. These patients are potentially subject to a multiplicity of damaging entities. The most prominent are prolonged duration of cardiopulmonary bypass (CPB) and its contactactivated inflammatory response, and prolonged aortic cross-clamping, with an increased likelihood of cardiac ischemia-reperfusion injury and a low cardiac output syndrome that, in turn, compromises renal blood flow and perfusion pressure. Additional exacerbating renal insults that inevitably occur with complex or complicated cardiac surgery include post-CPB hemodynamic instability with arrhythmias and compromised cardiac function; prolonged hypotension and the requirement for potent vasopressors such as norepinephrine in high doses; and bleeding and administration of multiple blood products.
Cardiopulmonary bypass
When off-pump coronary artery bypass grafting (OPCAB) was introduced, it was postulated that the avoidance of CPB and its inflammatory response might decrease the incidence and severity of CSA-AKI [15] .
A systematic review and meta-analysis of 22 randomized controlled trials (4819 patients) suggested that OPCAB may be associated with a lower incidence of CSA-AKI, although without a decrease in the requirement for RRT [16] . As always, definitive conclusions were limited by variability in the definition of AKI and other methodological problems. In contrast, the German OPCAB in Elderly Patients trial detected no difference in the incidence or severity of CSA-AKI by Acute Kidney Injury Network (AKIN) criteria in 1612 patients undergoing OPCAB versus coronary artery bypass grafting (CABG) with CPB [5 & ]. The CABG Off or On Pump Revascularization Study (CORONARY) investigators randomized 4752 patients in 79 centers in 19 countries to off-pump or on-pump CABG. There was no difference in the primary composite outcome measure of the 30-day rate of death, myocardial infarction, stroke, or renal failure requiring dialysis [17] . The same investigators conducted a kidney function substudy of this main study by adding further renal data collection for patients after recruitment had already begun [18] . Data for 2932 patients were analyzed. The risk of CSA-AKI was lower in the OPCAB group compared to the onpump group (relative risk 0.75-0.89 depending on the definition of AKI used). Interestingly, however, and contrary to the results of many observational studies [19] , there was no difference between the groups in the degree of renal injury present at 1 year. In other words, although OPCABG induced less CSA-AKI, this was not associated with better clinically meaningful or important outcomes. This serves to highlight the importance of confirming (or refuting) the results of observational studies with prospectively collected data from randomized clinical trials (RCTs) [20] . That being said, this is only one RCT, albeit large and multicenter. Ideally, the results of multiple such RCTs, meta-analyzed, would provide the best evidence for any association
KEY POINTS
Considerable progress has been made in more accurate definition of CSA-AKI and greater understanding of its pathophysiology; however, prevention and management of CSA-AKI remains a substantial challenge.
In time, the KDIGO criteria will likely supplant the RIFLE and AKIN criteria, but still do not come close to identifying AKI at the time of renal insult.
Of the many biomarkers currently under investigation, NGAL has emerged as the one most likely to become established for the early diagnosis of AKI.
Early initiation of RRT deserves further attention as a potential intervention to alter the clinical course of CSA-AKI. RCTs are warranted.
Hypotension during cardiopulmonary bypass
The optimal mean arterial pressure (MAP) to help prevent CSA-AKI during CPB is unknown [21] . Almost all studies that examine MAP during CPB are observational and have attempted to correlate hypotension with adverse neurologic outcome. Renal outcome studies have demonstrated conflicting data [22] [23] [24] .
Azau et al. [25] recently published results of a single-center randomized controlled study of 300 patients with known risk factors for AKI undergoing elective cardiac surgery with normothermic CBP. In the control group, MAP during CPB was targeted to 50-60 mmHg, whereas in the intervention group, the target was 75-85 mmHg. The average MAP achieved in the control and intervention groups was 60 AE 6 and 79 AE 6 mmHg, respectively. There was no intergroup difference in CSA-AKI, hospital LOS, or mortality.
Blood transfusion
Khan et al. [26 & ] examined the putative role of blood transfusion in causing CSA-AKI in 1210 adults undergoing cardiac surgery. Of these, 74% received no red blood cells (RBCs), 17% received two units RBCs or less, and 9% received more than two units RBCs. The authors defined AKI by a doubling of serum creatinine (SCr), but also measured urine interleukin-18 and neutrophil gelatinase-associated lipocalin (NGAL). After adjusting for 12 preoperative and surgical variables, the authors concluded that the risk of AKI was highest in patients receiving more than two units RBCs by all three end points. However, the authors also acknowledged that the study was limited by being observational: there was no set transfusion trigger; the age of RBCs was variable; and a direct causal relationship between RBC transfusion and AKI could not be confirmed.
Contrast-induced nephropathy
A substantial proportion of patients undergo contrast angiography or ventriculography prior to cardiac surgery. The risk of contrast-induced nephropathy (CIN) as a pathway to AKI is related to associated factors such as the type and dose of contrast medium, the patient's age, degree of underlying CKD, and state of hydration. CIN is induced by a number of pathways [27] , which may explain why no single intervention, including intravenous isotonic fluid hydration, sodium bicarbonate, N-acetylcysteine (NAC), fenoldopam, and statins among others has been shown to prevent CIN [28] . Only intravenous isotonic fluid hydration remains consistently recommended in guidelines that attempt to decrease the risk of CIN [28] .
An important question is whether extending the time period between angiography and cardiac surgery can decrease the risk of CIN. The 2011 American College of Cardiology Foundation/ American Heart Association Guideline for CABG Surgery states that 'in patients with pre-existing renal dysfunction, a delay of surgery after coronary angiography may be reasonable until the effect of radiographic contrast material on renal function is assessed' [29] . This recommendation is based on retrospective, single-center epidemiological studies using multivariable logistic regression showing an increase in the odds ratio of CSA-AKI when surgery was performed less than 5 days after angiography [30] [31] [32] . In contrast, Ö zkaynak et al. [33] found that time to surgery following angiography in a cohort of 573 consecutive patients was not a risk factor for the development of CSA-AKI. Given the dearth of prospective randomized studies, the most reasonable approach might be to attempt to evaluate for CIN prior to elective cardiac surgery, but not to delay urgent surgery to allow a longer interval after angiography.
DEFINITIONS, STAGING, AND EPIDEMIOLOGY OF CARDIAC SURGERY-ASSOCIATED ACUTE KIDNEY INJURY
For decades, there was no standard definition or staging system for the diagnosis of AKI and more than 30 different and often arbitrary definitions were used over time [34] . This greatly limited our ability to compare epidemiologic studies or prognosticate outcomes. An agreed consensus definition was necessary to improve the consistency of study inclusion and exclusion criteria as well as defined, standardized, clinical end points (Table 1) .
In 2004, Bellomo et al. [34] introduced the RIFLE classification, which defined and staged renal failure over 7 days into five classes of increasing severity: risk, injury, failure, loss of renal function, and endstage kidney disease ( Table 1 ). The Risk, Injury, and Failure criteria were based upon changes in SCr, estimated (not measured) glomerular filtration rate (eGFR), and/or urine output. This group of investigators subsequently formed the AKIN and in 2007 published the so-called AKIN criteria [35] (Table 1) . This made several practical refinements. The chronic criteria (loss and end-stage renal disease) as well as eGFR were discarded, decreasing the classification from five to three stages (AKIN Stages 1, 2, [41] declared the KDIGO criteria to be superior to AKIN and RIFLE with regard to prognostic power. This is also suggested by a single-center observational study in the general ICU population, where the KDIGO criteria demonstrated greater sensitivity to detect AKI and predict in-hospital mortality [42] . Machado et al. [4] used KDIGO criteria in a retrospective analysis of a cohort of 2804 patients and found that even slight changes in renal function are independent predictors of 30-day mortality. These studies suggest that in time the KDIGO criteria will supplant the RIFLE and AKIN criteria, but still do not come close to identifying AKI at the time of renal insult.
A number of surgical scoring systems that incorporate SCr have been developed to help predict overall morbidity and mortality in patients undergoing cardiac surgery. The most commonly used are the Society of Thoracic Surgeons Score, a risk model used to predict operative morbidity and mortality after adult cardiac surgery. The Euroscore II system for cardiac operative risk evaluation utilizes the eGFR based upon the preoperative SCr.
MONITORING RENAL FUNCTION AND ACUTE KIDNEY INJURY
In order to determine whether AKI has occurred, or is likely to occur, biomarkers and physiological indicators have been studied.
Renal biomarkers
The RIFLE, AKIN, and KDIGO criteria have enormously helped in defining and staging AKI. However, they all have important limitations. First, they were not designed for the early diagnosis of perioperative AKI, given that they are based upon changes in SCr occurring 48 hours to 7 days after the original insult. Moreover, SCr is affected by age, sex, ethnicity, muscle mass, diet, drugs, and intravascular volume loading, independently of renal function [43, 44] . Thus, rescue interventions based upon RIFLE, AKIN, or KDIGO criteria may be instituted far too late to ameliorate intraoperative or early perioperative AKI [45] . Second, urine output criteria are notoriously unreliable in predicting AKI, and there is no effort to differentiate prerenal from intrarenal oliguria or ischemic from nephrotoxic kidney injury [46] [47] [48] . AKI may occur in the absence of oliguria [49] and oliguria may be the consequence of extrarenal obstruction [50] .
These limitations have spurred the search for biomarkers of early AKI that might timely direct intervention that could alter renal outcomes ( [54] found that plasma NGAL measured as early as 3 hours after CPB was a much stronger predictor of AKI and the need for early medical intervention than SCr.
Cystatin C is a low-molecular-weight protein that is rapidly filtered by the glomerulus. When GFR decreases, serum cystatin C levels increase before elevations in SCr. There are a number of studies that suggest that cystatin C may be a useful early predictor of AKI in cardiac surgery patients [6, 46, 55, 56] . In a prospective cohort study, the Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury-AKI Consortium enrolled 1147 adults undergoing cardiac surgery and found that preoperative cystatin C was superior to SCr and eGFR in predicting the risk of postoperative AKI [6] . A similar conclusion was reached in a multicenter, prospective study of 288 children [57] . In contrast, another prospective cohort study conducted on 1150 high-risk adult cardiac surgery patients found that cystatin C levels were less sensitive than SCr for detection of AKI, but were able to identify which patients were at substantially higher risk for AKI with adverse outcomes [55] .
In a prospective study of 616 patients undergoing cardiac surgery, Wang et al. [56] found that the level of preoperative serum cystatin C combined with the severity of dipstick proteinuria were accurate predictors of the 179 patients who developed postoperative AKI defined by AKIN Stage 1 criteria. High preoperative cystatin C levels and heavy proteinuria were associated with a high incidence of preoperative CKD, hyperuricemia, heart failure, or recent myocardial infarction, indicative of multifactorial risk factors for postoperative AKI.
There are a number of other biomarkers that have been investigated but very few are clinically used. Often, biomarkers that show promise in small single-center trials have not yet been subject to larger prospective trials. For example, Meersch et al. [58] decided to study urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7), which are both inducers of cell cycle arrest in the mechanism of AKI. In 50 patients undergoing high-risk cardiac surgery with CPB, they found that elevated TIMP-2 times IGFBP7, that is, Ã [IGFBP7], detected AKI within 4 hours of CPB compared with 1-3 days for SCr. A decline in Ã [IGFBP7] was the strongest predictor of renal recovery.
Billings et al. [59] examined the hypothesis that intravascular hemolysis induced during cardiac surgery releases plasma-free hemoglobin that in turn induces heme oxygenase-1. In patients who developed AKI after cardiac surgery, peak-free hemoglobin levels correlated with peak heme oxygenase-1, and heme oxygenase-1 levels increased with duration of CPB and interleukin activation. This biomarker might help identify the pathogenesis of AKI rather than its early detection.
Most clinical scoring systems designed to predict CAS-AKI use SCr to classify CKD and renal risk [60] . Simonini et al. [61] found that the inclusion of endogenous ouabain, another newer biomarker, improved the predictive ability of the New England Cardiovascular Disease Study Group score prediction.
In sum, of the many biomarkers currently under investigation, NGAL has emerged as the one most likely to become established for the early diagnosis of AKI. Its practicability will depend on the development of an easy-to-use and inexpensive point-ofcare kit that could be used in the operating room or ICU.
Renal oximetry
Perioperative optimization of renal tissue oxygenation is of paramount importance, especially in the renal medulla, where, because of sluggish blood flow that facilitates urinary concentration, tissue PO 2 is less than 10 mmHg [14] . Renal tissue oxygenation could be maintained by support of intravascular volume, hemoglobin concentration, oxygen saturation, cardiac output, and renal perfusion pressure.
Choi et al. [62 & ] conducted a prospective observational study of regional renal oximetry (rSO 2 ) using near-infrared spectroscopy and attempted to correlate it with CSA-AKI by RIFLE criteria. The device was placed on 100 patients undergoing elective cardiac surgery with CPB, with a renal depth of less than 40 mm from the skin, and simultaneous cerebral oximetry. At the time of initiation of CPB, both cerebral and renal rSO 2 declined; however, rSO 2 , thereafter, trended back toward the baseline. On separation from CPB, cerebral oximetry readings quickly returned to baseline, whereas rSO 2 gradually decreased. Patients who developed CSA-AKI appeared to have increased duration of low rSO 2 (<55%). Similar to most initial studies, this study raises more questions than it answers -such as, what intervention should be made in response to a given level of rSO 2 that would alter renal outcome? [63] .
THERAPEUTIC INTERVENTIONS IN ACUTE KIDNEY INJURY
A number of drug therapies have been studied as potential preventive agents for AKI as has the timing of RRT initiation.
Preoperative statin therapy
There is some evidence that stains might prevent AKI, but most of the studies are on animals, or retrospective and inconclusive. Molnar et al. [64 & ] evaluated the effects of continuing preoperative statins versus discontinuing them for 24 hours in 625 adult patients undergoing elective cardiac surgery operations. There was no difference in AKI defined by a doubling of SCr or requirement for RRT. However, in patients who continued statins until the time of surgery, a battery of renal biomarkers were significantly decreased, including urine interleukin-18, urine and plasma NGAL, and urine kidney injury molecule-1. These findings are supportive of prospective controlled studies to further define the potential renoprotective role of statins.
Preoperative acetylsalicylic acid and preoperative chronic kidney disease
In prior observational studies, preoperative and early postoperative aspirin therapy in cardiac surgery has been associated with decreased overall morbidity, mortality, and CSA-AKI [65] [66] [67] [68] . A recent retrospective cohort study suggests that preoperative acetylsalicylic acid may have a protective effect against AKI in patients with preoperative CKD [69] . The severity of CKD is calculated by the Modification of Diet in Renal Disease algorithm, which classifies it as Stages 1-5 based upon an eGFR of greater than 90, 60-89, 30-59, 15-29, and less than 15 ml/min/1.73 m 2 , respectively. The greatest benefit of preoperative acetylsalicylic acid in decreasing the incidence and severity of AKI as well as mortality appeared to be in patients with Stages 4 and 5 CKD (eGFR <30 ml/min/1.73 m 2 ). The authors postulated that this might reflect the antiinflammatory and antiplatelet effects of acetylsalicylic acid, but also recognized that a retrospective study cannot establish direct cause and effect. The putative protective role of acetylsalicylic acid thus awaits definition by prospective studies.
N-Acetylcysteine
NAC has been extensively studied as a protective agent in CIN [70] , but because the evidence is conflicting, it is not routinely recommended as a preventive therapy. Because its putative mechanism of renal protection is via its antioxidant properties [71] , NAC has also been studied for the possible prevention of CSA-AKI. However, meta-analyses do not confirm a consistent benefit in decreasing the risk of CSA-AKI or other important clinical outcomes [72, 73] . A major challenge in analyzing multiple studies is the variability in NAC dose, route of administration, baseline renal function, and type and dose of contrast medium.
Santana-Santos et al. [74] recently published results of a small, single-center RCT of high-dose NAC (150 mg/kg, then 50 mg/kg infusion over 6 hours) in 70 patients with Stage 3 or 4 CKD undergoing CABG surgery with or without CPB. The primary end point was AKI defined by AKIN criteria. The incidence of AKI by AKIN was 29% in patients who received NAC versus 57% in those who did not, although in more than 80% of patients, the severity of AKI was limited to Stage 1. The authors found that NAC constrained an increase in reactive oxidative species (reflected by thiobarbituric-acid-reactive substance levels) and suggested this as a possible mechanism for its protective effect. There was an important interaction with CPB. The incidence of AKI in patients who had CPB and did not receive NAC was 63%, compared with only 8% in patients who received NAC and had OPCAB surgery. These findings emphasize the multifactorial and interactive pathogenesis of CSA-AKI.
Sodium bicarbonate
Similar to NAC, sodium bicarbonate has been investigated as a possible preventive agent in CIN, through a similar mechanism of reduction in tubular oxidative stress [75] . Results of trials have been inconsistent, and urinary alkalinization is currently not recommended for the prevention of CIN [76] .
Urinary alkalinization has also been evaluated as a possible protective intervention in cardiac surgery. Turner et al. [77] recently reported the results of a multicenter RCT of sodium bicarbonate versus 0.9% isotonic saline in patients at high risk for CSA-AKI. At the planned interim analysis after 123 patients had been enrolled, there was no difference in CSA-AKI; therefore, the study was stopped on the grounds of futility.
Tian et al. [78] performed a meta-analysis of trials of sodium bicarbonate in cardiac surgery that included five RCTs and one prospective observational cohort study (a total of 1673 patients). There was no difference in the incidence of CSA-AKI.
Early initiation of renal replacement therapy
There has been considerable debate on the most favorable timing of RRT after the onset of AKI. Nephrologists often balk at early intervention because of lack of evidence of benefit, expense, and the potential for complications of therapy. These include problems associated with vascular access, rapid fluid and electrolyte shifts, hemodynamic instability, and disequilibrium syndromes related to cerebral edema. On the contrary, delayed RRT subjects patients to the many hazards or uremia such as encephalopathy, aspiration, platelet dysfunction and bleeding, impaired wound healing, and resistance to infection. The advent of continuous renal replacement therapy (CRRT) has obviated many of these concerns by facilitating the early and practical application of RRT while avoiding hemodynamic instability in susceptible patients after cardiac surgery.
Liu et al. [79 & ] conducted a systematic review and meta-analysis of nine retrospective cohort studies and two RCTs of early versus late initiation of CRRT in critically ill patients with CSA-AKI. Most of these investigations were published between 2002 and 2011, and included a total of 841 patients. Analysis of the overall results suggested that early CRRT was associated with shorter ICU LOS and decreased 28-day mortality. Similar meta-analyses, in general, critical care populations, have also indicated a benefit from early initiation of CRRT [80, 81] . However, as the authors caution, almost all studies are retrospective and observational, with inconsistent definitions of 'early' and 'late' CRRT. A definitive answer to this question awaits the conduct of prospective RCTs.
CONCLUSION
Given the complex pathogenesis of CSA-AKI, it is unlikely that its incidence can be significantly reduced by any one intervention. Just as a combination of factors working in concert leads to this clinical syndrome, prevention and treatment of CSA-AKI requires a multimodal approach where both the premorbid condition of the patient and the particular idiosyncrasies of the cardiac surgical procedure itself are taken into account. Timely intervention requires early recognition of potential and actual kidney injury. The research published in the last 18 months reflects the numerous approaches being taken to address CSA-AKI. Although there have been few practice-changing articles published during the period covered by this review, the research that has been cited here is, for the most part, of relatively high quality. It is by studying indicators and interventions in differing settings in differing populations that we can come to a better understanding of their real merit through inclusion in systematic reviews and meta-analyses. The research cited here adds further depth to our understanding of CSA-AKI and builds upon an enormous fund of existing knowledge.
